“We are delighted that Kirkstall have decided to offer Alvetex scaffold at the heart of their 3D Quasi-Vivo platform” commented Richard Rowling, Commercial Director at Reinnervate. “Alvetex scaffold is becoming the industry standard for scientists who need to retain the native structure and functionality of cells to better mimic in-vivo biological models” he added.
The two companies aim to launch the new joint product at the Kirkstall-sponsored 'Advances in in-vitro cell culture’ meeting in Utrecht on 22-23 May 2012.
Malcolm Wilkinson, CEO of Kirkstall Ltd said, “life scientists are beginning to realise that perfusion based cell culture systems can significantly improve the biological relevance of in- vitro cell based assays. The Quasi-Vivo system already helps many leading laboratories improve the predictive accuracy of their ADMET studies. The early data we have that combines perfusion based cell culture with 3D cell growth shows stunning differences when compared to traditional 2D approaches.”